FDA Approves Selumetinib for Paediatric Patients 1 Year of Age and Older with Neurofibromatosis Type 1 with Symptomatic, Inoperable Plexiform Neurofibromas By Ogkologos - September 25, 2025 213 0 Facebook Twitter Google+ Pinterest WhatsApp Approval was based on findings from the Study 89, SPRINT and the SPRINKLE trials Source RELATED ARTICLESMORE FROM AUTHOR Rare Disease Day 2026: Advancing equity for people living with rare cancers in Europe EMA Recommends Extension of Therapeutic Indications for Ponatinib Updated Oncogene-Addicted mNSCLC Living Guideline v1.3 MOST POPULAR How to Cope With and Discuss an Uncertain Cancer Prognosis: An... September 7, 2023 FDA Approves Azacitidine for Newly Diagnosed Juvenile Myelomonocytic Leukaemia June 2, 2022 EMA Recommends Extension of Therapeutic Indications for Selinexor June 15, 2022 Motivational Speaker Shares Her 11-Year Battle With Breast Cancer In New... November 16, 2021 Load more HOT NEWS Hopes for the future of cancer research – a video from... Checking in on our Mental Health Adding Pembrolizumab to Standard Chemotherapy, Followed by Pembrolizumab Maintenance, Results in... For Early-Stage Cervical Cancer, Minimally Invasive Surgery Declining
